Form 4: Amylyx Pharmaceuticals Co-CEO Joshua Cohen Exercises Stock Options
SEC Form 4 Filing
Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, exercised stock options and acquired 34,449 shares of common stock on September 12, 2024.
Summary
- On September 12, 2024, Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, exercised stock options to acquire 34,449 shares of common stock at a price of $1.57 per share.
- Following this transaction, Cohen directly owns 3,237,301 shares of Amylyx Pharmaceuticals common stock.
- Cohen also directly owns 1,857 stock options.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock option exercises, so the sentiment is neutral.
Industry Context
This is a standard SEC Form 4 filing, which is required when a company insider, such as a director or officer, buys or sells shares of the company's stock. It provides transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the increase in the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 09/12/2024 | Date of transaction: Joshua Cohen exercised stock options. |
| 09/16/2024 | Date of signature on the Form 4 filing. |
| 02/26/2025 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.